Melincoff Gwen A 4
4 · Protalix BioTherapeutics, Inc. · Filed Oct 3, 2023
Insider Transaction Report
Form 4
Melincoff Gwen A
Director
Transactions
- Award
Stock Options (Right to Buy)
2023-09-29+61,676→ 61,676 totalExercise: $1.66Exp: 2033-09-29→ Common Stock (61,676 underlying)
Footnotes (2)
- [F1]The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
- [F2]Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.